drugset / Trial / NCT00210353

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

NCT00210353

RandomizedParallel-groupOpen-labelTreatment

Summary

Assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone. In April 2006, a third arm of treatment was added to compare the antitumor activity and safety of rituximab alone vs chlorambucil alone

Timeline

Start
2003-01
Primary completion
2015-04
Completion
2016-02-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Chlorambucil Other / unclassified 6 mg/m2 Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications